HIKMA’S EYEING A REINVENTION (BUY; 22% UPSIDE)
12/01/22 -" Unlike Smaller Pharmas’ lackluster performance (up 16% since the March 2020 lows vs. 73% gain for STOXX600) since the COVID-19 outbreak, Hikma (Buy, UK) – a generics manufacturer, leveraging market ..."
Pages
51
Language
English
Published on
12/01/22
You may also be interested by these reports :
05/11/25
The Q3 results missed expectations, as Novo contended with competition from compounding pharmacies and Eli Lilly. Moreover, the management again ...
04/11/25
The Q3 operating profitability exceeded expectations, though sales fell short of consensus. The management reaffirmed its full-year guidance. While ...
03/11/25
BioNTech reported mixed Q3 results. Sales significantly exceeded market expectations, but the operating loss was higher than anticipated. The 2025 ...
31/10/25
Novo has locked horns with Pfizer by proposing to acquire obesity-focused Metsera, after Pfizer had made an offer in September 2025. Metsera’s ...